| Specificity |
This product is specific for Palivizumab |
| Host Species |
Mouse |
| Immunogen |
Palivizumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.001-0.1 µg/ml |
| Competitive ELISA |
5-30 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
This product is lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1,κ |
| Clonality |
Monoclonal |
| Clone ID |
7B3 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
ELISA binding of Anti-Palivizumab Antibody (7B3), mAb, Mouse (GenScript, A02112-40) with Palivizumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Palivizumab, 1 µg/ml.
Anti-Palivizumab Antibody (7B3), mAb, Mouse (GenScript, A02112-40) dilution start from 1,000 ng/ml.
EC50= 4.418 ng/ml.
Anti-Palivizumab Antibody (7B3) (GenScript, A02112-40) blocks Palivizumab binding with Human RSV F recombinant protein.
Coating antigen: Palivizumab 1 µg/ml.
RSV F final concentration: 100 ng/ml.
Anti-Palivizumab antibody dilutions start from 30 μg/ml.
IC50= 0.821 µg/ml.
Standard curve of Palivizumab Sandwich ELISA. The Palivizumab Sandwich ELISA assay is developed by using Anti-Palivizumab Antibody (7B3), mAb, Mouse (GenScript, A02112-40) and Anti-Palivizumab Antibody (2F12), mAb, Mouse (GenScript, A02111-40) as the capture and detection antibodies, respectively.
In this ELISA assay, Anti-Palivizumab Antibody (2F12), mAb, Mouse (GenScript, A02111-40) was labeled with Biotin.
GenScript can provide customized conjugation services for this product per the customer's request.
The sensitivity of detecting Palivizumab is up to 0.6 ng/ml.
| Target Background |
Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process. Anti-Palivizumab Antibody (7B3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Palivizumab. |
| Synonyms |
Mouse monoclonal to Palivizumab//Synagis |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
